The Oxford Vaccine Group is a vaccine research group within the Department of Paediatrics at the University of Oxford.

During the past decade, Oxford Vaccine Group conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 1 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Oxford Vaccine Group" #1 sponsor was "University of Oxford" with 12 trials, followed by "Novartis Vaccines" with 2 trials sponsored, "ILiAD Biotechnologies" with 1 trials sponsored, "Janssen Vaccines & Prevention B.V." with 1 trials sponsored and "Pfizer" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Oxford Vaccine Group" #1 collaborator was "Novartis" with 2 trials as a collaborator, "Brigham and Women's Hospital" with 1 trials as a collaborator, "GlaxoSmithKline" with 1 trials as a collaborator, "Imperial College London" with 1 trials as a collaborator and "Mason Medical Research Trust" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Oxford Vaccine Group" are "Influenza" (2 trials), "Meningitis" (2 trials), "Meningococcal Disease" (2 trials), "Septicaemia" (2 trials) and "Antibody Persistance After Booster Dose of Men C Vaccine" (1 trials). Many other conditions were trialed in "Oxford Vaccine Group" in a lesser frequency.

Most popular intervention types in "Oxford Vaccine Group" are "Biological" (13 trials), "Drug" (2 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "1/5th dose MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)" (1 trials), "10-valent pneumococcal conjugate vaccine" (1 trials), "13-valent pneumococcal conjugate vaccine" (1 trials), "Ad26.RSV.preF (1*10^11 vp)" (1 trials) and "Ad26.RSV.preF (5*10^10 vp)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Oxford Vaccine Group" are 18 trials for "All" genders.

Currently, there are NaN active trials in "Oxford Vaccine Group". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in Oxford Vaccine Group, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Oxford Vaccine Group, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".